Stoney’s VKTX bought out?
“
“Viking Therapeutics'
Viking Therapeutics Inc.'s stock (VKTX) soared 61% early Tuesday, after the company announced positive results from a Phase 2 trial of its weight-loss drug VK2735, a GLP-1 receptor agonist that it's developing in both injectable and oral...